Abstract:The growing number of chemicals in the current consumer and industrial markets presents a major challenge for regulatory programs faced with the need to assess the potential risks they pose to human and ecological health. The increasing demand for hazard and risk assessment of chemicals currently exceeds the capacity to produce the toxicity data necessary for regulatory decision making, and the applied data is commonly generated using traditional approaches with animal models that have limited context in terms of human relevance. This scenario provides the opportunity to implement novel, more efficient strategies for risk assessment purposes. This study aims to increase confidence in the implementation of new approach methods in a risk assessment context by using a parallel analysis to identify data gaps in current experimental designs, reveal the limitations of common approaches deriving transcriptomic points of departure, and demonstrate the strengths in using high-throughput transcriptomics (HTTr) to derive practical endpoints. A uniform workflow was applied across six curated gene expression datasets from concentration-response studies containing 117 diverse chemicals, three cell types, and a range of exposure durations, to determine tPODs based on gene expression profiles. After benchmark concentration modeling, a range of approaches was used to determine consistent and reliable tPODs. High-throughput toxicokinetics were employed to translate in vitro tPODs (µM) to human-relevant administered equivalent doses (AEDs, mg/kg-bw/day). The tPODs from most chemicals had AEDs that were lower (i.e., more conservative) than apical PODs in the US EPA CompTox chemical dashboard, suggesting in vitro tPODs would be protective of potential effects on human health. An assessment of multiple data points for single chemicals revealed that longer exposure duration and varied cell culture systems (e.g., 3D vs. 2D) lead to a decreased tPOD value that indicated increased chemical potency. Seven chemicals were flagged as outliers when comparing the ratio of tPOD to traditional POD, thus indicating they require further assessment to better understand their hazard potential. Our findings build confidence in the use of tPODs but also reveal data gaps that must be addressed prior to their adoption to support risk assessment applications.

Application and interpretation of immunophenotyping data in safety and risk assessment

Interpretation of Toxicogenomics Data

Immunophenotyping, Part II: Analysis of Nanoparticle Effects on the Composition and Activation Status of Human Peripheral Blood Mononuclear Cells

Experiences with an advanced screening procedure for the identification of chemicals with an immunotoxic potential in routine toxicology

Consensus on the Key Characteristics of Immunotoxic Agents as a Basis for Hazard Identification

Immunotoxicant screening and prioritization in the twenty-first century

Application of genomics in preclinical drug safety evaluation.

Development of the ICH Guidelines for Immunotoxicology Evaluation of Pharmaceuticals Using a Survey of Industry Practices

Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology

Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective

Relative sensitivities of TDAR, cytokine production, and immunophenotyping assays in immunotoxicity assessment

Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum

A Genomic and Bioinformatics Approach

Progress in toxicogenomics to protect human health

Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations

Recent advances in immunotoxicity and its impact on human health: causative agents, effects and existing treatments

New approach methodologies to enhance human health risk assessment of immunotoxic properties of chemicals — a PARC (Partnership for the Assessment of Risk from Chemicals) project

From vision toward best practices: Evaluating in vitro transcriptomic points of departure for application in risk assessment using a uniform workflow

Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs

High-content analysis/screening for predictive toxicology: application to hepatotoxicity and genotoxicity.

Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS